Evidence Sufficient to Support the Use of This Procedure With Normal
TIRAT CARMEL, Israel, Nov. 27, 2011 /CNW/ - InSightec Ltd announced that
NICE, the National Institute for Health and Clinical Excellence of the
NHS in the UK, announced new favorable guidelines for the treatment of
uterine fibroids using MR guided Focused Ultrasound. The new guidelines
state that the current evidence on the efficacy of magnetic resonance
image (MRI)-guided transcutaneous focused ultrasound treatment for
uterine fibroids and evidence on safety are adequate to support the use
of this procedure under normal arrangements.
As part of the interventional procedures evaluation process the
committee reviewed dozens of peer reviewed papers describing over one
thousand patients treated with ExAblate system.
The Specialist Advisers listed key efficacy outcomes as quality of life,
symptom improvement, avoidance of further surgery, and subsequent
fertility. NICE made a point of stating that the Committee was informed
that many women wish to avoid more invasive interventions for
symptomatic fibroids, even if this choice carries an increased chance
of requiring further treatments. Some women choose this procedure
because they wish to preserve their fertility.
"We are delighted with this news which recognizes the importance of MR
guided focused ultrasound as a non-invasive uterine-sparing treatment
option for women," stated Dr. Kobi Vortman, President and CEO of
InSightec Ltd. "NICE is world renown and these new guidelines should
help build awareness of this breakthrough, non-invasive outpatient
technology to women and their physicians around the world."
The new guidelines (IPG413) replace previous guidelines (IPG231) issued
InSightec Ltd. is a privately-held company owned by Elbit Imaging,
General Electric, MediTech Advisors, LLC and employees. It was founded
in 1999 to develop the breakthrough MR guided Focused Ultrasound
technology and transform it into the next generation operating room.
Headquartered near Haifa, Israel, the company has over 130 employees
and has invested more than $150 million in research, development, and
clinical investigations. Its U.S. headquarters are located in Dallas,
Texas. ExAblate has won several awards for innovation and its potential
to help mankind including the 2004 Wall St. Journal Technology
Innovation Awards - Bronze Medal and Second Place and the 2004 European
Union's IST grand prize for innovation and potential to benefit
mankind. Time Magazine recently included it among the 50 best
SOURCE InSightec Ltd
For further information:
+1-866-645-6663 x0 x309